BACKGROUND: Treatment options for metastatic colorectal cancer (CRC) are limited after a fluoropyrimidine, oxaliplatin and irinotecan; novel agents need to be explored in this setting. Dasatinib, an oral inhibitor of Src family kinases, inhibits proliferation in CRC cell lines and has antitumor activity in CRC xenograft models. PATIENTS AND METHODS: We conducted a multi-center phase II trial of dasatinib in unresectable, previously-treated metastatic CRC patients. No more than 2 prior chemotherapy regimens were permitted, which must have contained a fluoropyrimidine, oxaliplatin and irinotecan. The primary endpoint was progression-free survival (PFS) at 4 months. The Simon two-stage design required that at least 5 of the first 19 patients be progression-free at 4 months to expand to a second stage. RESULTS: Nineteen patients enrolled at 9 centers. The study was terminated after the first stage due to lack of efficacy. There were no objective responses; 1 patient (5%) had stable disease for 7.3 months. The PFS rate at 4 months was 5.3% (90% CI: 0.3, 22.6). Median PFS was 1.6 months (90% CI: 1.4, 1.8). Median overall survival was 5.1 months (90% CI: 2.4, 6.3). Grade 3/4 toxicities included fatigue in 16% of patients, and anemia, anorexia, nausea/vomiting and dyspnea in 11%. CONCLUSION: Dasatinib is inactive as a single agent in previously treated metastatic CRC patients.
BACKGROUND: Treatment options for metastatic colorectal cancer (CRC) are limited after a fluoropyrimidine, oxaliplatin and irinotecan; novel agents need to be explored in this setting. Dasatinib, an oral inhibitor of Src family kinases, inhibits proliferation in CRC cell lines and has antitumor activity in CRC xenograft models. PATIENTS AND METHODS: We conducted a multi-center phase II trial of dasatinib in unresectable, previously-treated metastatic CRC patients. No more than 2 prior chemotherapy regimens were permitted, which must have contained a fluoropyrimidine, oxaliplatin and irinotecan. The primary endpoint was progression-free survival (PFS) at 4 months. The Simon two-stage design required that at least 5 of the first 19 patients be progression-free at 4 months to expand to a second stage. RESULTS: Nineteen patients enrolled at 9 centers. The study was terminated after the first stage due to lack of efficacy. There were no objective responses; 1 patient (5%) had stable disease for 7.3 months. The PFS rate at 4 months was 5.3% (90% CI: 0.3, 22.6). Median PFS was 1.6 months (90% CI: 1.4, 1.8). Median overall survival was 5.1 months (90% CI: 2.4, 6.3). Grade 3/4 toxicities included fatigue in 16% of patients, and anemia, anorexia, nausea/vomiting and dyspnea in 11%. CONCLUSION:Dasatinib is inactive as a single agent in previously treated metastatic CRC patients.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Heike Aligayer; Douglas D Boyd; Markus M Heiss; Eddie K Abdalla; Steven A Curley; Gary E Gallick Journal: Cancer Date: 2002-01-15 Impact factor: 6.860
Authors: Jennifer M Golas; Judy Lucas; Carlo Etienne; Jonathan Golas; Carolyn Discafani; Latha Sridharan; Erwin Boghaert; Kim Arndt; Fei Ye; Diane H Boschelli; Fangbiao Li; Craig Titsch; Christine Huselton; Inder Chaudhary; Frank Boschelli Journal: Cancer Res Date: 2005-06-15 Impact factor: 12.701
Authors: George D Demetri; Patricia Lo Russo; Iain R J MacPherson; Ding Wang; Jeffrey A Morgan; Valerie G Brunton; Prashni Paliwal; Shruti Agrawal; Maurizio Voi; T R Jeffry Evans Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531
Authors: Neil P Shah; Hagop M Kantarjian; Dong-Wook Kim; Delphine Réa; Pedro E Dorlhiac-Llacer; Jorge H Milone; Jorge Vela-Ojeda; Richard T Silver; H Jean Khoury; Aude Charbonnier; Nina Khoroshko; Ronald L Paquette; Michael Deininger; Robert H Collins; Irma Otero; Timothy Hughes; Eric Bleickardt; Lewis Strauss; Stephen Francis; Andreas Hochhaus Journal: J Clin Oncol Date: 2008-06-09 Impact factor: 44.544
Authors: Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang Journal: J Clin Oncol Date: 2008-03-03 Impact factor: 44.544
Authors: John H Strickler; Shannon McCall; Andrew B Nixon; John C Brady; Herbert Pang; Christel Rushing; Allen Cohn; Alexander Starodub; Christy Arrowood; Sherri Haley; Kellen L Meadows; Michael A Morse; Hope E Uronis; Gerard C Blobe; S David Hsu; S Yousuf Zafar; Herbert I Hurwitz Journal: Invest New Drugs Date: 2013-11-01 Impact factor: 3.850
Authors: S M Reddy; S Kopetz; J Morris; N Parikh; W Qiao; M J Overman; D Fogelman; I Shureiqi; C Jacobs; Z Malik; C A Jimenez; R A Wolff; J L Abbruzzese; G Gallick; C Eng Journal: Invest New Drugs Date: 2015-06-12 Impact factor: 3.850
Authors: Thomas C Beadnell; Katie M Mishall; Qiong Zhou; Stephen M Riffert; Kelsey E Wuensch; Brittelle E Kessler; Maia L Corpuz; Xia Jing; Jihye Kim; Guoliang Wang; Aik Choon Tan; Rebecca E Schweppe Journal: Mol Cancer Ther Date: 2016-05-24 Impact factor: 6.261
Authors: Swadesh K Das; Santanu Maji; Stephen L Wechman; Praveen Bhoopathi; Anjan K Pradhan; Sarmistha Talukdar; Devanand Sarkar; Joseph Landry; Chunqing Guo; Xiang-Yang Wang; Webster K Cavenee; Luni Emdad; Paul B Fisher Journal: Pharmacol Res Date: 2020-02-13 Impact factor: 7.658